Astaxanthin and Aerobic Training After 65: What We Know

Antioxidants usually get a warning label in endurance science: take enough of them during training, and they may dampen the reactive oxygen species that help muscles build more mitochondria. That makes a 2022 trial in adults aged 65 to 82 genuinely interesting. After 12 weeks of aerobic interval walking, men taking an astaxanthin-containing supplement reportedly oxidized about 0.76 g of fat during a graded treadmill test, versus 0.23 g with placebo.

The result could mean that older muscle responds differently to antioxidant support than younger, well-trained muscle. It could also be a fragile subgroup finding from a small secondary analysis of a multi-ingredient product. Both interpretations fit the evidence. For now, this is a worthwhile hypothesis, not a reason to expect an astaxanthin capsule to upgrade every walk into a metabolic masterclass.

Why this finding runs against the usual training advice

Exercise-generated reactive oxygen species, or ROS, are not simply cellular exhaust. In appropriate amounts, they help activate signaling pathways involved in endurance adaptation, including AMPK, p38 MAPK, and PGC-1α-driven mitochondrial biogenesis. A 2021 review by Jordan et al. describes evidence that supplemental vitamin C, vitamin E, and N-acetylcysteine can blunt some endurance-training adaptations by reducing that signal.

The case is not that oxidation is healthy in unlimited quantities. Chronic oxidative stress damages tissue. The question is whether an antioxidant lowers excessive background oxidative stress or erases the short-lived signal produced by exercise. A 2022 review of muscle and vascular aging reports that aging commonly involves higher baseline oxidative stress, mitochondrial dysfunction, and persistent inflammation. That gives the older-adult hypothesis a biological rationale: a moderate antioxidant might restore a dysregulated redox environment instead of suppressing a useful exercise signal.

It remains a rationale, not a demonstrated mechanism for astaxanthin during training. The relevant human trial did not measure PGC-1α, mitochondrial biogenesis markers, longitudinal redox biomarkers, or insulin sensitivity.

What the 12-week trial actually tested

In the Liu et al. randomized, double-blind, placebo-controlled trial, adults aged 65 to 82 completed 12 weeks of interval incline walking three times weekly. Training progressed to 80% to 85% of maximum heart rate. Participants received either placebo or two daily capsules of AstaReal AX: 12 mg astaxanthin, 10 mg tocotrienol, and 6 mg zinc.

Fifty-eight people enrolled, but 40 completed the graded exercise treadmill test used for the metabolic analysis, an attrition rate of about 31%. After exclusion of one female outlier more than two standard deviations from the mean, the reported analysis included 17 men and 22 women. The treadmill protocols also differed by sex: men walked at 3.3 mph with incline rising 1% each minute, while women walked at 3.0 mph with 2.5% incline increases every three minutes.

The reported positive result came from the male subgroup. Men assigned to the supplement had roughly 3.3 times the fat oxidation measured during the graded treadmill test as men assigned to placebo: approximately 0.76 g versus 0.23 g. Women showed no statistically significant between-group difference. The study describes these metabolic outcomes in a secondary analysis of an earlier muscle-strength trial, so they do not carry the same weight as a pre-specified primary endpoint in a trial designed and powered around fat oxidation.

The main problem: this was not an astaxanthin-only experiment

The study tested a combination product, not pure astaxanthin. Tocotrienol is a vitamin E-family compound with independent antioxidant, anti-inflammatory, and metabolic effects that could matter in skeletal muscle; zinc adds another biologically active ingredient. The male result therefore belongs to the full formulation. It cannot tell us whether astaxanthin caused the effect, tocotrienol caused it, zinc contributed, or the combination mattered.

A 2026 review of astaxanthin and muscle metabolism describes plausible astaxanthin-specific actions involving lipid oxidation, mitochondrial membrane integrity, antioxidant enzymes, and inflammatory signaling. Plausibility helps scientists choose what to test. It does not separate ingredients after the fact, and it does not establish improved training adaptation in older adults.

The available publication text also does not provide the effect sizes, 95% confidence intervals, or multiplicity-adjusted p-values needed to judge how precisely the male subgroup result was estimated. Per-arm counts for men are not explicitly reported; based on the total number of male completers, each arm appears to have contained only about 8 to 10 men. That is too few for a confident sex-stratified efficacy claim. The lack of an explicit conflict-of-interest disclosure in the available text also makes it harder to assess the role, if any, of the manufacturer of the branded product in study design or reporting.

The female result is part of the headline

The larger female cohort showed no significant benefit for fat oxidation. That does not prove the supplement fails in older women; a null result in a small study can reflect imprecision as well as no effect. It does mean the trial does not support a sex-neutral recommendation.

Different treadmill protocols for men and women further complicate any attempt to explain the sex difference. They created different exercise stress profiles, so the trial cannot cleanly distinguish sex-specific biology from protocol-related effects. Other supplements can affect exercise-related outcomes in older women under other conditions. For example, a 2023 crossover trial of dietary nitrate in 18 older women examined muscle fatigue and recovery after an acute beetroot-juice dose. That finding does not explain astaxanthin's null result, but it does rule out the lazy conclusion that older women simply do not respond to nutritional interventions.

Does aging change the antioxidant calculus?

There is human evidence that correcting a severe redox deficit can improve function in older adults outside a training program. In a 2022 pilot randomized trial of glycine plus N-acetylcysteine, older adults improved measures of glutathione deficiency, oxidative stress, mitochondrial dysfunction, insulin resistance, and muscle strength. GlyNAC is not astaxanthin, and the study did not pair supplementation with structured aerobic training. Still, it supports the broader idea that antioxidant restoration may behave differently in older people with impaired redox status than in younger athletes.

Likewise, a randomized omega-3 trial in healthy older adults found improved skeletal-muscle function and acute exercise response. Omega-3s work mainly through anti-inflammatory pathways rather than the antioxidant mechanism proposed here, so they are not direct evidence for astaxanthin. They show that nutrition can modify muscle-related exercise outcomes in later life.

Evidence in younger or fitter populations does not settle the question either. Liu et al. cite a 2013 study in endurance-trained male athletes that found no effect of astaxanthin on time-trial performance or fat oxidation. A 2024 controlled trial in physically active firefighters provides another non-elderly comparison, but it cannot answer whether adults over 65 with greater baseline oxidative stress respond differently.

Verdict: interesting signal, premature supplement strategy

The most defensible conclusion is narrow. One small secondary analysis found higher treadmill-test fat oxidation in older men taking a three-ingredient astaxanthin formulation while completing 12 weeks of aerobic interval training. The same study found no significant effect in women. High attrition, small sex-stratified groups, different testing protocols by sex, absent mechanistic measures, and the inability to attribute results to astaxanthin all limit the claim.

Older adults with documented oxidative stress or glutathione deficiency may be the right population for a serious trial of antioxidant support during training. That trial should use pure astaxanthin versus placebo, enroll enough men and women for separate analyses, pre-specify metabolic endpoints, track redox and mitochondrial markers, analyze all randomized participants when possible, and disclose commercial relationships clearly. Until then, 12 mg per day of single-ingredient astaxanthin would test a cleaner personal hypothesis than the mixture used in Liu et al., but the evidence does not show that it will improve training adaptation—or that it will do so in women.

Confidence: low to moderate. The age-specific redox hypothesis is credible; the direct clinical evidence is one limited trial.